Enhertu Breast Cancer Treatment: New Hope as Life-Extending Drug Becomes Available on the NHS
A significant development in cancer care has brought renewed hope to patients living with advanced breast cancer in England. The Enhertu breast cancer treatment is now becoming available through the NHS in England for eligible patients with HER2-low advanced or metastatic breast cancer, following a change in the position on NHS access.
The decision is particularly significant because trastuzumab deruxtecan, marketed as Enhertu, had previously not been recommended for routine NHS use in England for this particular group of patients on cost-effectiveness grounds. The latest development means that around 1,000 patients each year in England are expected to be eligible for the treatment.
For patients, families and oncology professionals, the announcement represents more than the introduction of another medicine. It demonstrates the increasing importance of targeted cancer treatments, molecular classification and personalised medicine within modern NHS oncology services.
At Niche Healthcare, we closely follow developments across cancer diagnosis, treatment and supportive care because advances in oncology can have important implications for clinical teams, hospital services and healthcare procurement.
What Is Enhertu?
Enhertu is the brand name for trastuzumab deruxtecan, an antibody-drug conjugate designed to target cancer cells expressing the HER2 protein.
Antibody-drug conjugates represent an increasingly important area of precision oncology. They combine a targeted antibody with an anti-cancer medicine. The antibody is designed to recognise a particular target on cancer cells and deliver the attached medicine more selectively.
Enhertu is already used in several cancer treatment settings, but the latest NHS development concerns patients with a particular form of advanced breast cancer known as HER2-low breast cancer.
Historically, breast cancers have often been classified as either HER2-positive or HER2-negative. Developments in cancer research have shown that this distinction can be more complex. Some tumours that are not classified as conventionally HER2-positive still express relatively low levels of the HER2 protein.
This group is referred to as HER2-low.
Recognising HER2-low disease as a clinically relevant category has created opportunities for more personalised treatment strategies and demonstrates why accurate pathology and molecular characterisation are increasingly important in cancer care.
For further information on NHS cancer services, visit:
Why the Enhertu Breast Cancer Treatment Decision Matters
The availability of the Enhertu breast cancer treatment is particularly important because it applies to patients with advanced or metastatic disease.
Metastatic breast cancer means that cancer has spread from the breast to another part of the body. Although treatments can often control the disease and help people live longer, metastatic breast cancer is generally not considered curable.
Treatment therefore focuses on controlling cancer, delaying progression, managing symptoms, maintaining quality of life and extending survival wherever possible.
Clinical evidence considered during the assessment of trastuzumab deruxtecan demonstrated improvements in both progression-free and overall survival compared with conventional chemotherapy in the relevant patient population.
Reports surrounding the latest NHS decision indicate that Enhertu can provide almost seven additional months of life on average for eligible patients, although individual outcomes vary considerably and some patients may experience substantially different results.
This is an important distinction. An average clinical-trial result cannot predict how long an individual patient will benefit from treatment. Treatment suitability and likely outcomes need to be discussed with the patient’s specialist oncology team.
From Rejection to NHS Availability
The journey towards NHS access has attracted considerable attention.
In 2024, NICE did not recommend trastuzumab deruxtecan for HER2-low metastatic or unresectable breast cancer after chemotherapy because its assessment concluded that the cost-effectiveness estimates were above the range considered an acceptable use of NHS resources.
The medicine was already available for this indication through NHS Scotland, creating considerable discussion about differences in access across the UK.
Patients, healthcare professionals and breast cancer charities subsequently campaigned for wider access.
The position has now changed following further negotiations and changes affecting the assessment of medicines. Reports on the new agreement indicate that around 1,000 women each year in England could benefit from access to Enhertu.
The development highlights one of the most complex challenges facing modern healthcare systems: balancing rapid access to innovative treatments with clinical effectiveness, safety, affordability and the responsible use of finite NHS resources.
Healthcare professionals and procurement teams can follow current NICE recommendations at:
Information about NHS cancer services and treatment pathways is also available at:
The Growing Importance of Precision Medicine in Breast Cancer
The Enhertu announcement reflects a much broader transformation taking place in oncology.
Cancer treatment is increasingly moving away from approaches based solely on the location of a tumour. Clinicians can now use information about receptors, proteins, genetic alterations and other biomarkers to understand the biological characteristics of an individual patient’s cancer.
That information can help determine which treatments are most likely to work.
HER2 status is a good example.
As our understanding of HER2 expression has developed, the traditional distinction between HER2-positive and HER2-negative disease has become more detailed. Identifying HER2-low tumours can potentially open another treatment pathway for patients who would previously have been considered HER2-negative.
This places additional importance on high-quality pathology, immunohistochemistry and diagnostic laboratory services.
Niche Healthcare supplies laboratory and diagnostic equipment to healthcare organisations, including an Open Reagent Automatic Immunohistochemistry Staining System, which can be viewed at:
Open Reagent Automatic Immunohistochemistry Staining System
The role of laboratory diagnostics extends far beyond any single medicine. Reliable pathology processes are fundamental to accurately classifying cancers and helping multidisciplinary teams make evidence-based treatment decisions.
What Does This Mean for Oncology Teams?
Introducing a new treatment option does not simply involve prescribing a medicine. Modern systemic anti-cancer therapy depends on a wider clinical infrastructure.
Patients may require diagnostic testing before treatment, baseline clinical assessments, venous access, medication preparation, administration facilities, monitoring and management of treatment-related adverse effects.
Specialist oncology nurses, pharmacists, oncologists, pathology teams, laboratory professionals and other healthcare staff all contribute to safe treatment pathways.
This means developments in cancer medicines can have wider operational implications for oncology departments.
As treatment becomes increasingly personalised, healthcare services also need appropriate infrastructure to support more complex diagnostic and therapeutic pathways.
Patient Safety and Monitoring Remain Essential
Although access to an effective new treatment is positive news, Enhertu is a specialist cancer medicine and can cause significant adverse effects.
Patients receiving systemic anti-cancer treatments require careful assessment and ongoing monitoring in accordance with the relevant clinical guidance, medicine information and local protocols.
One particularly important recognised risk associated with trastuzumab deruxtecan is interstitial lung disease or pneumonitis. Other adverse effects can include nausea, fatigue and effects on blood cell counts, among others.
Clinical teams therefore need to monitor patients appropriately and investigate potential treatment-related symptoms promptly.
This illustrates an important principle across oncology: improved access to innovative medicines must be accompanied by robust safety systems, trained healthcare professionals, effective monitoring and appropriate supportive care.
Supporting Safe Oncology Treatment Environments
The continued development of cancer treatment also reinforces the importance of reliable clinical equipment and consumables throughout oncology services.
Niche Healthcare supplies healthcare organisations with a broad range of products supporting hospitals, clinics, laboratories and specialist clinical departments.
For example, reliable venous access can form an important part of treatment pathways for patients requiring repeated intravenous therapies. The Niche Healthcare Single Lumen PICC Line can be viewed at:
Single Lumen Peripherally Inserted Central Catheter (PICC) for Long-Term Intravenous Therapy
Niche Healthcare also supplies ward-ready extravasation kits designed to support clinical teams where an extravasation incident occurs during intravenous treatment:
Extravasation Kits (Ward-Ready) – Niche Healthcare
These products are not specific requirements for Enhertu and should always be selected and used according to local clinical protocols, individual patient requirements and relevant professional guidance. However, they illustrate the wider clinical infrastructure required to deliver safe systemic anti-cancer therapy.
Healthcare professionals can explore the wider Niche Healthcare range at:
Healthcare Supplies UK | NHS Medical Supplier | Niche Healthcare
Supporting Patient Dignity During Clinical Care
Alongside treatment safety and clinical infrastructure, maintaining patient dignity and comfort is an important consideration across cancer services.
Patients undergoing cancer investigations or treatment may need to change clothing for examinations, diagnostic procedures, imaging, treatment or other clinical interventions.
Niche Healthcare supplies the:
Dignity Gown for Clinical Support
The single-use gown is designed to provide practical patient coverage within clinical environments while supporting dignity during examinations, procedures and treatment.
It may be relevant across oncology departments, outpatient treatment areas, diagnostic departments and other healthcare environments where patients need appropriate clinical clothing or coverage.
This is particularly relevant when considering cancer care from the patient’s perspective. High-quality treatment is not limited to the medicine being administered; the surrounding clinical experience, privacy, dignity, communication and comfort also matter.
The PICC line, extravasation kit and dignity gown are not being presented as specific requirements for Enhertu treatment. Products should always be selected and used according to individual patient requirements, local clinical protocols and appropriate professional guidance.
Instead, they demonstrate some of the wider equipment, consumables and patient-support products that may be required across modern oncology and hospital environments.
Healthcare professionals and procurement teams can explore the wider range at:
Healthcare Supplies UK | NHS Medical Supplier | Niche Healthcare
What Does the Decision Mean for Patients?
For eligible patients, the most important consequence is an additional treatment option.
Advanced breast cancer treatment is rarely a single-stage process. Patients may move through different therapies depending on the biological characteristics of their cancer, previous treatments, treatment response, side effects and disease progression.
Adding another effective treatment to this pathway can potentially give clinicians more options for controlling disease.
For some patients and families, additional months without cancer progression or additional overall survival can be extremely meaningful.
However, Enhertu will not be suitable for every person with breast cancer. Eligibility depends on the specific characteristics of the cancer, previous treatments and other clinical considerations.
Patients should therefore discuss treatment options directly with their breast cancer or oncology team rather than assuming that a particular medicine will be appropriate based on a diagnosis alone.
A Wider Shift Towards Personalised Cancer Care
The Enhertu decision comes during a period of rapid development in cancer medicine.
Genomic testing, immunotherapy, antibody-drug conjugates, targeted treatments and increasingly sophisticated diagnostic technologies are changing how cancers are classified and treated.
Niche Healthcare recently explored another important example of this trend: research examining whether genomic testing could help some breast cancer patients safely avoid unnecessary chemotherapy.
You can read the article here:
Breast Cancer Chemotherapy: Could Millions of Patients Safely Avoid Treatment?
Although reducing unnecessary treatment and introducing additional life-extending treatments may appear to be very different objectives, they are connected by the same principle: giving the right treatment to the right patient.
The future of cancer care is increasingly personalised rather than uniform.
What Could This Mean for NHS Cancer Services?
New treatment options can create both opportunities and operational considerations for NHS organisations.
Oncology services need to accommodate changing treatment pathways while maintaining safe staffing, pharmacy capacity, diagnostic services, treatment facilities and monitoring systems.
Pathology services may also become increasingly important as more therapies depend upon specific biomarkers.
From a procurement perspective, healthcare organisations need reliable access to appropriate clinical consumables, diagnostic equipment, patient-support products and treatment infrastructure.
Niche Healthcare works with NHS trusts and other healthcare organisations to source and supply products across oncology, pathology, laboratory, ward and wider clinical environments.
Our wider healthcare range is available at:
Healthcare Supplies UK | NHS Medical Supplier | Niche Healthcare
Frequently Asked Questions About Enhertu
What is Enhertu?
Enhertu is the brand name for trastuzumab deruxtecan, an antibody-drug conjugate used to treat certain cancers. It combines an antibody targeting HER2 with an anti-cancer medicine, helping deliver treatment to cells expressing HER2.
Is Enhertu now available on the NHS in England?
Yes. The latest decision means eligible patients in England with the relevant form of HER2-low advanced or metastatic breast cancer can access the treatment through the NHS. Eligibility is determined by specialist clinical teams according to the approved treatment criteria.
What is HER2-low breast cancer?
HER2-low describes breast cancer cells that express some HER2 protein but not enough to meet the traditional definition of HER2-positive disease. Advances in targeted therapies have made this classification increasingly relevant because certain treatments can target cancers with these lower levels of HER2 expression.
Does Enhertu cure metastatic breast cancer?
No. Metastatic breast cancer is generally considered incurable. Treatments such as Enhertu aim to control disease, delay progression and extend survival. Individual responses vary, and patients should discuss expected benefits and risks with their oncology team.
Is Enhertu suitable for every breast cancer patient?
No. Breast cancer includes many different biological subtypes, and Enhertu is used only in particular circumstances. Treatment decisions depend on factors including HER2 status, previous treatments, disease stage, overall health and specialist clinical assessment.
Conclusion: A Significant Development in Breast Cancer Treatment
The arrival of the Enhertu breast cancer treatment for eligible NHS patients in England represents an important development in the treatment of advanced breast cancer.
For approximately 1,000 patients expected to become eligible each year, the decision provides access to an additional therapy capable of extending survival and delaying disease progression.
It also demonstrates how rapidly breast cancer treatment is evolving. HER2-low disease, antibody-drug conjugates and increasingly detailed tumour classification show how precision medicine is creating treatment opportunities that would have been difficult to envisage only a relatively short time ago.
At the same time, innovative medicines depend upon the wider healthcare system around them. Accurate diagnostics, specialist oncology teams, safe medicine administration, effective monitoring, infection prevention and dependable clinical supplies all contribute to high-quality cancer care.
Niche Healthcare continues to support NHS trusts, hospitals, laboratories and specialist clinical teams with healthcare products and procurement support across the UK.
Explore the Niche Healthcare range:
Healthcare Supplies UK | NHS Medical Supplier | Niche Healthcare
For authoritative information about cancer services and NHS treatment, visit:
For current technology appraisal guidance and recommendations, visit:
Enhertu Breast Cancer Treatment
See our full selection:
Healthcare Supplies in Aberdeen | Niche Healthcare
Healthcare Supplies in Basildon | Niche Healthcare
Healthcare Supplies in Basingstoke | Niche Healthcare
Healthcare Supplies in London | Niche Healthcare
For procurement details, bulk purchasing, and further product information, contact our team today on 01274 965089 or check out our website at www.nicheofficesolutions.co.uk / www.nicheofficesolutions.co.uk/niche-nhs
Further clinical information can be found on our blog page: www.nicheofficesolutions.co.uk/category/niche-healthcare-news
For products not found on our online website, please view our Healthcare catalogues: www.nicheofficesolutions.co.uk/healthcare-catalogues
View our Healthcare YouTube videos Playlist
If you have any additional questions, drop us an email at info@nicheofficesolutions.co.uk